Italian Journal of Dermatology and Venereology最新文献

{"title":"Ectodermal dysplasia/skin fragility syndrome: first Italian case due to a new homozygous mutation in the PKP1 gene.","authors":"Riccardo Balestri, Davide Geat, Francesca Rivieri, Annalisa Pedrolli, Ilaria Palmieri, Enza M Valente, Stefania Termine, Aldo Naselli, Laura Nai Fovino, Danila D'Onofrio, Laura Rizzoli","doi":"10.23736/S2784-8671.25.08197-6","DOIUrl":"10.23736/S2784-8671.25.08197-6","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"379-381"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.","authors":"Federica Scarfì, Michele Lanzetti, Serena Rosati, Franca Taviti","doi":"10.23736/S2784-8671.25.08222-2","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08222-2","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"160 4","pages":"386-388"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of onabotulinumtoxinA in treating platysma prominence asymmetry and cervical pain: case report of two patients.","authors":"Ilaria Proietti, Agnieszka Dybala, Emanuele Amore, Guida Stefania, Concetta Potenza","doi":"10.23736/S2784-8671.25.08208-8","DOIUrl":"10.23736/S2784-8671.25.08208-8","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"384-385"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omalizumab: a broader role in dermatology? Evidence and the road ahead.","authors":"Aditya K Bubna, Vinayak Viplav","doi":"10.23736/S2784-8671.25.08144-7","DOIUrl":"10.23736/S2784-8671.25.08144-7","url":null,"abstract":"<p><p>Omalizumab is a humanized monoclonal IgG1 antibody approved by the US-FDA for the treatment of chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines. The aim of this review is to outline the utility of omalizumab in all types of urticarias, as well as other off-label dermatological disorders. A comprehensive literature search was conducted to identify studies evaluating the utility of omalizumab in dermatology. Databases searched included PubMed, Medline, and Embase. All original studies including case reports, case series and clinical trials were included if they were full-text, involved a dermatologic disorder treated with omalizumab and published in English. Articles were excluded if they were conference abstracts, non-clinical reports, or invitro studies. Apart from CSU, the efficacy of omalizumab has been demonstrated in atopic dermatitis (AD), bullous pemphigoid (BP), hyper IgE syndrome (HIES), mastocytosis, and Kimura's disease (KD), with the level of evidence varying for each disorder. Besides, in anecdotal reports, the benefits of omalizumab in TEN and Netherton Syndrome has been highlighted. Omalizumab offers a promising therapeutic option for a variety of dermatologic disorders beyond CSU. Further research is needed to optimize treatment protocols and establish definitive guidelines for omalizumab use in these conditions to facilitate quicker disease remission, improved safety, and reduced reliance on conventional immunosuppressants. However, the high cost of omalizumab remains a significant barrier for its widespread use in developing countries.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"323-336"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the treatment of male androgenetic alopecia: current options and emerging therapies.","authors":"Aditya K Gupta, Mesbah Talukder, Shruthi Polla Ravi, Daniel Taylor, Tong Wang","doi":"10.23736/S2784-8671.25.08183-6","DOIUrl":"10.23736/S2784-8671.25.08183-6","url":null,"abstract":"<p><strong>Introduction: </strong>Androgenetic alopecia (AGA), or pattern hair loss, is the most common form of hair loss worldwide. It is primarily caused by genetic and hormonal factors, particularly the action of dihydrotestosterone (DHT) on hair follicles.</p><p><strong>Evidence acquisition: </strong>A comprehensive literature search on PubMed and Google Scholar was conducted until October 31, 2024, using keywords related to male AGA and its treatments. Relevant reviews, meta-analyses, clinical trials, and case studies in English were selected and analyzed to enhance the quality of the research. This review is based solely on existing studies and does not include new human or animal research conducted by the authors.</p><p><strong>Evidence synthesis: </strong>This review thoroughly examined and analyzed 149 articles to provide a detailed presentation of the evidence.</p><p><strong>Conclusions: </strong>This article examines both established and emerging therapies for AGA. We recommend initiating treatment with topical minoxidil and oral finasteride, as these are extensively researched and FDA-approved options for male AGA. For patients who do not respond well or cannot tolerate these treatments, clinicians may explore alternative therapies and approaches.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"344-361"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malar bags: clinical features and therapeutic options.","authors":"Benedetta Fanelli, Giorgio Maullu, Maria G Onesti, Nicolò Scuderi","doi":"10.23736/S2784-8671.25.08098-3","DOIUrl":"10.23736/S2784-8671.25.08098-3","url":null,"abstract":"<p><p>Malar bags are a common aesthetic concern characterized by swelling and puffiness in the prezygomatic space and cheek area. Various medical and surgical techniques have been developed to address this condition and restore a more youthful and rejuvenated appearance. In terms of medical therapies, non-invasive options such as topical creams containing retinoids, peptides, and hyaluronic acid have shown promise in reducing mild malar bags. These substances help improve skin texture, promote collagen production, and enhance skin elasticity, thereby reducing the appearance of swelling and puffiness. Additionally, injectable treatments such as dermal fillers have been utilized to camouflage malar bags and create a smoother contour. By strategically placing fillers in the surrounding areas, a skilled practitioner can achieve a more harmonious facial appearance. In recent years, advancements in radiofrequency have also shown promise for treating malar bags. Laser skin resurfacing procedures can help tighten the skin, stimulate collagen production, and reduce the appearance of swelling and wrinkles in the malar area. For patients seeking more lasting results, surgical techniques provide viable options. Blepharoplasty, a surgical procedure aimed at correcting eyelid issues, can be performed to remove excess skin and fat deposits in the lower eyelid, effectively addressing malar bags. Additionally, newer techniques like endoscopic surgery allow for minimal incisions and reduced scarring, making them appealing to patients concerned about visible postoperative marks. Although numerous medical and surgical techniques are available, the choice of treatment depends on factors such as the severity of the condition, patient preferences, and the expertise of the medical practitioner. In this manuscript we have made a retrospective evaluation of the medical and surgical therapies of malar bags and we report our considerations after 20 years of experience.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"314-322"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender perspective in the management of psoriasis.","authors":"Martina Maurelli, Paolo Gisondi, Giampiero Girolomoni","doi":"10.23736/S2784-8671.25.08147-2","DOIUrl":"10.23736/S2784-8671.25.08147-2","url":null,"abstract":"<p><p>Gender medicine has been achieving increasing importance. Gender differences in disease depend on hormonal status and may involve functions of the skin, immune responses and metabolic pathways, and have to do also with indications and response to treatments. Psoriasis is a common chronic inflammatory immune-mediated disease. The prevalence of psoriasis in the population is balanced between males and females, but early onset psoriasis is slightly more prevalent in males, with the latter suffering from a more severe disease. In general, male and female patients receive identical drugs at equivalent dosages. However, females receive systemic treatments less frequently compared to males. Males are more satisfied with their psoriasis treatment and respond better to biologics. Females have a significant higher rate of adverse events and drug-related discontinuation rate compared to males. About conventional systemic treatments for psoriasis during pregnancy, only cyclosporine is suggested when the benefits exceed the potential side effects, whereas methotrexate is contraindicated during pregnancy and lactation and in the three months before fatherhood and motherhood. Among the biologics, only certolizumab pegol is considered safe in pregnant patients, as it does not cross the maternal-placental barrier. Therefore, it is important to consider a gender perspective in the treatment of psoriasis, including her willingness to procreate. This is a narrative review highlighting the challenges that the healthcare dermatologists may face regarding management of psoriasis in female patients.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"337-343"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bee-sting therapy.","authors":"Stefano Veraldi, Gianluca Nazzaro","doi":"10.23736/S2784-8671.25.08226-X","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08226-X","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"160 4","pages":"388-389"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a questionnaire for the detection of flares in atopic dermatitis treated with biologics and small molecules: a pilot study.","authors":"Luca Mastorino, Michela Ortoncelli, Nicole Macagno, Giovanni Cavaliere, Niccolò Siliquini, Pietro Quaglino, Simone Ribero","doi":"10.23736/S2784-8671.25.08034-X","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08034-X","url":null,"abstract":"<p><strong>Background: </strong>Proper identification and management of flare in atopic dermatitis (AD) is complex, especially in patients being treated with biological drug or small molecules. To date, the definition of flare is not agreed upon. Available scores such as the ADCT (AD control tool) are administered retrospectively to the patient and do not cover key aspects such as self-medication with topical steroids. In the present pilot study, we propose a daily questionnaire to be administered to the patient for proper identification of flares.</p><p><strong>Methods: </strong>Patients under dupilumab, tralokinumab and upadacitinib filled out for all days in the first month of treatment a daily questionnaire focused on pruritus and topical steroids application. During the in-clinic visit, the physician based on the diary will assess the number and presence of: 1) increase in NRSp (numerical rating score, pruritus) score ≥4 compared to the previous day; 2) increase in topical steroid or topical calcineurin inhibitor applications ≥1 compared with the previous day. Flares were defined as worsening from the previous condition daily, meaning an increased itching or increase of steroid or calcineurin inhibitor application. Topical medication application is considered good proxy for worsening of disease that is easily recorded by the patient.</p><p><strong>Results: </strong>Forty-seven patients completed at least 1-month questionnaires. Thirteen patients reported at least one flare, and 6 of these patients reported clinical flares (pruritus) in the first months of treatment. Most reported a single episode, while 2 patients reported 2 episodes during the first month, 1 patient reported 15 episodes during the first month, and all three of these patients were on dupilumab. Regarding dupilumab, 38% of patients experienced at least one episode of flares in the first month. 17% of patients on tralokinumab experienced flares. No patients experienced flares on upadacitinib.</p><p><strong>Conclusions: </strong>The pilot and observational nature does not allow validation of the questionnaire-used, which therefore needs wider integration in clinical use and studies confirming its usefulness. Implementing a questionnaire such as ours that evaluates flares in clinical practice could optimize the therapeutic management of the atopic patient being treated with systemic medication whether biologic or small molecules.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"160 4","pages":"304-308"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical recommendations for oncological psoriatic patients: flow chart and statement.","authors":"Giovanni Pellacani, Ketty Peris, Giuseppe Argenziano, Luca Bianchi, Andrea Conti, Annunziata Dattola, Rosa Falcone, Paolo Gisondi, Maria E Greco, Michele Milella, Stefano Piaserico, Francesca Prignano, Antonio G Richetta, Paolo Marchetti","doi":"10.23736/S2784-8671.25.08192-7","DOIUrl":"10.23736/S2784-8671.25.08192-7","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"377-379"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}